• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Here Are the First 10 Drugs Biden Will Target for Price Negotiations
WASHINGTON (AP) — The popular diabetes treatment Jardiance and the blood thinner Eliquis are among the first drugs that will be targeted for price negotiations in effort to cut Medicare costs. President Joe Biden’s administration on Tuesday released a list of 10 drugs for which the federal government will take a first-ever step: negotiating drug prices directly with the manufacturer. [time-brightcove not-tgx=”true”] The move is expected to cut costs for some patients but faces litigation from the drugmakers and heavy criticism from Republican lawmakers. It’s also a centerpiece of t...
Source: TIME: Health - August 29, 2023 Category: Consumer Health News Authors: TOM MURPHY, AMANDA SEITZ and CHRIS MEGERIAN / AP Tags: Uncategorized wire Source Type: news

The nationwide Finnish anticoagulation in atrial fibrillation (FinACAF): study rationale, design, and patient characteristics
AbstractAtrial fibrillation (AF) is a major cause of ischemic stroke and the number of AF patients is increasing. Thus, up-to-date multifaceted data about the characteristics of AF patients, their treatments, and outcomes are urgently needed. The Finnish anticoagulation in atrial fibrillation (FinACAF) study has collected comprehensive data on all Finnish AF patients from 1st January 2004 to 31st December 2018. The aim of this paper is to describe the study rationale, the process of integrating data from the applied resources and to define the study cohort. Using national unique personal identification number, individual p...
Source: European Journal of Epidemiology - January 5, 2022 Category: Epidemiology Source Type: research

Costs of surgical ablation of atrial fibrillation in Ontario, Canada from 2006 to 2017
ConclusionOntario taxpayers spend significant financial resources on surgical ablation of AF, a procedure lacking high ‐quality evidence demonstrating benefit in reducing mortality or stroke. Further large prospective studies examining clinically important outcomes are needed to justify its routine use in patient care and to guide allocation of healthcare funds.
Source: Journal of Cardiac Surgery - September 27, 2020 Category: Cardiovascular & Thoracic Surgery Authors: Justin Y. Chow, Graham McClure, Emilie P. Belley ‐Côté, William F. McIntyre, Rohit K. Singal, Richard P. Whitlock Tags: ORIGINAL ARTICLE Source Type: research